OncoMatch/Clinical Trials/NCT05528055
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Is NCT05528055 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including SCR-6920 capsule and SCR-6920 capsule for solid tumor.
Treatment: SCR-6920 capsule · SCR-6920 capsule · SCR-6920 capsule · SCR-6920 capsule — A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available
Cannot have received: systemic anti-cancer therapy
systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry
Cannot have received: radiation therapy
Radiation therapy within 2 weeks prior to study entry
Cannot have received: autologous hematopoietic stem cell transplantation
Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose
Lab requirements
Blood counts
Adequate organ function (as defined in the protocol)
Kidney function
Adequate organ function (as defined in the protocol)
Liver function
Adequate organ function (as defined in the protocol)
Cardiac function
Clinically significant cardiac abnormalities (as defined in the protocol)
Adequate organ function (as defined in the protocol). Clinically significant cardiac abnormalities (as defined in the protocol).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify